Clinical Trials Browser

Terminated × INDUSTRY × magrolimab × Clear all

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05330429 2025-07-01

ELEVATE CRC

Phase 2 Terminated

77 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT04827576 2025-05-08

ELEVATELung&UC

Phase 2 Terminated

106 enrolled 22 charts

Other solid neoplasm

Solid Tumor

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Phase 2 Terminated

54 enrolled 26 charts

Myeloid Malignancies

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03922477 2022-02-21

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

13 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute